Omeros Corporation announced the appointments of two new Vice Presidents. Cathy Melfi, Ph.D. will lead Omeros' regulatory department as Vice President, regulatory affairs and quality systems. Albert Yu, M.D. will join the company's clinical department as vice president, clinical development, where oversight of Omeros' multiple clinical-stage programs will be divided between him and Steve Whitaker, M.D., the company's Vice President, clinical development and chief medical officer. Dr. Melfi brings 17 years of experience in the pharmaceutical industry and 11 years of experience in academia, covering the fields of regulatory affairs and health economics and outcomes research.

She has provided strategic and technical input into the development and commercialization of pharmaceutical products across all phases of development. She joins Omeros from Eli Lilly and Company, where she held technical and leadership roles of increasing scope and responsibility in Global Health Outcomes and Regulatory Affairs. Dr. Yu has over 20 years of clinical drug development experience, spanning small molecules to biologics and all phases of development.

His background covers a wide range of therapeutic areas, including cardiovascular, central nervous system, respiratory and infectious disease. Prior to joining Omeros, Dr. Yu served as Vice President of clinical affairs and Chief Medical Officer of Calistoga Pharmaceuticals Inc. until its acquisition by Gilead Sciences Inc. in 2011.